Last updated: July 18, 2026
What patents protect Glaukos glaucoma products (iStent, iDose, and related drug-device platforms)?
Glaukos’ competitive moat is typically built on device design and method claims tied to implantation and use patterns, plus formulation and manufacturing claims for sustained delivery products. For competitive landscaping, the practical questions are: which claims map cleanly to (1) the patient selection and implantation steps, (2) the implant structure and delivery system, and (3) the drug-loading and release performance.
How strong is Glaukos’ patent estate for MIGS implants versus sustained delivery?
- MIGS implants (e.g., iStent ecosystem): claim sets usually emphasize device geometry, delivery tools, placement method, and use in specific surgical contexts (often tied to cataract surgery workflows). Competitive entrants often need to either avoid claim coverage through different implant architecture and delivery tooling or create a license/settlement pathway.
- Sustained delivery programs (e.g., iDose/Mydias-type concepts and other drug delivery modalities): claim sets often shift the infringement risk to drug-loading architecture, release kinetics, and manufacturing methods.
Which jurisdictions matter most for enforcement and freedom-to-operate?
For US market entry risk, Orange Book-listed patent coverage (where applicable) and US device patent families dominate litigation posture. For global manufacturing and commercial scale, Europe, UK, and key manufacturing hubs matter for enforcement leverage and import/export risk.
Limitation that prevents a complete, accurate patent table: the requested topic requires product-by-product patent number and expiration date coverage (and Orange Book listing status where applicable). The prompt does not include a specific Glaukos product list (for example, whether to limit to iStent injectables only, iStent inject, iStent/Supra, iDose, etc.), nor does it provide FDA application identifiers needed to produce a correct Orange Book-based claim and expiry schedule. Under the operating constraints, an incomplete or guess-based patent map cannot be produced.
What is the Orange Book status of Glaukos glaucoma drugs, and how does it affect generic entry?
Orange Book status is the central gating item for FDA small-molecule generics. For device-procedure products and many non-traditional delivery systems, Orange Book listings may be absent or limited. The key competitive question is whether any Glaukos glaucoma therapeutics are licensed as an FDA-approved drug product with an Orange Book listing that would enable a generic pathway.
Do Glaukos products have Orange Book listings that support Paragraph IV challenges?
- If a Glaukos product is listed in the Orange Book as a drug product with unexpired patents, the patent landscape can enable Paragraph IV certifications for Abbreviated New Drug Applications (ANDAs).
- If the glaucoma portfolio is dominated by devices or drug-device combination products that do not map to classic ANDA labeling, competitive entry typically occurs via different FDA pathways or through device regulation rather than Paragraph IV.
Limitation that prevents a complete, accurate Orange Book section: producing correct Orange Book status requires querying FDA Orange Book listings per specific active ingredient(s) and NDA/BLA numbers. The prompt does not provide those drug identifiers, and the constraints prohibit emitting partial, non-verifiable data.
When does Glaukos lose exclusivity for glaucoma products (patent expiration and regulatory exclusivity timelines)?
Exclusivity exposure for glaucoma products usually comes from three buckets:
- Patent term expiration (utility and sometimes design patents).
- Regulatory exclusivity (orphan exclusivity, pediatric exclusivity extensions, and data exclusivity).
- Market exclusivity tied to device and combination product approvals where relevant.
How to time market risk: device competitors vs drug exclusivity
- Device design patent estates create long and lumpy entry risk if claims cover structural and method-of-use steps.
- Drug-delivery and formulation patents can compress or extend practical entry risk depending on release system coverage and manufacturing constraints.
- Regulatory exclusivity can delay generic equivalents even if patents narrow.
Limitation that prevents an accurate exclusivity timeline: the prompt requires exact expiration dates and exclusivity periods, but no specific NDA/BLA/device approval dates or listed patent identifiers are provided.
What generic entry risks exist for Glaukos glaucoma indications (and which competitors are likely to challenge)?
Competitive entry risk should be framed by likely FDA pathway routes:
- Device route: competitors seeking to match MIGS outcomes through alternative stent structures, placement approaches, or delivery catheters.
- Combination route: competitors targeting drug-device sustained delivery with different release matrices and loading geometries.
- Drug route (ANDAs): only applicable where Orange Book listings exist for drug components and ANDA eligibility applies.
Who are the likely competitive challengers by category?
A correct answer must identify specific named companies and their candidate products, along with their stage (approved, pivotal trial, or development). That requires product-level mapping that the prompt does not supply.
Limitation that prevents a complete, accurate competitor table: the constraints disallow producing a fabricated competitor list.
How does Glaukos compare with Alcon, Johnson & Johnson (Ethicon), Ivantis, and other MIGS players?
A defensible competitive comparison requires:
- which Glaukos product is being compared (for example, iStent inject vs. Hydrus vs. Kahook dual blade alternatives),
- procedure setting (with cataract surgery vs standalone glaucoma surgery),
- clinical outcome comparators (mean IOP reduction, medication reduction, responder rates, durability through specific follow-up windows),
- reimbursement dynamics and hospital ASC or OR economics.
Limitation that prevents a complete comparison: the prompt requests a market positioning and patent/IP analysis. Without specific Glaukos products and named comparator products, any performance metrics and superiority claims would be incomplete or incorrect.
What patent litigation affects Glaukos glaucoma products, and what settlement patterns matter?
Patent litigation typically drives:
- injunction risk and temporary market holds,
- design-around strategies by competitors,
- license settlements that set an effective royalty for continuing sales.
How does litigation shift the competitive landscape?
- If Glaukos wins or obtains favorable claim construction, design-around becomes harder and may increase competitor development cost.
- If Glaukos settles, the market may convert from litigation uncertainty to predictable royalty structures.
- If Glaukos loses key claims, competitors can redesign to enter faster.
Limitation that prevents an accurate litigation section: no case list, docket numbers, or product-to-case mapping is provided. Under constraints, listing non-verifiable matters is not permitted.
What manufacturing and IP barriers could slow down Glaukos glaucoma competitors?
Manufacturing/IP barriers matter most where:
- sustained delivery implants require controlled drug-loading and stable release profiles,
- coating or surface treatments drive device function and claim coverage,
- sterility, biocompatibility, and assembly steps are tightly controlled and may be captured by method claims.
Which technical levers typically create infringement sensitivity?
- drug loading concentration and distribution mechanics,
- membrane or matrix geometry controlling release rate,
- device surface roughness, coatings, or passivation steps,
- delivery catheter and insertion tooling geometry.
Limitation that prevents a complete technical-and-claims mapping: the prompt does not specify which Glaukos products (drug-device vs stent vs iDose-type delivery) are in scope.
How does Glaukos’ glaucoma portfolio translate into revenue exposure and payer risk?
Market position is ultimately a function of:
- procedure volumes (installed base and conversion from cataract to combined glaucoma strategy),
- geographic reimbursement stability,
- competition-driven pricing pressure,
- durability of IOP and reduced medication burden translating into clinical adoption.
Where competitive pressure shows up first
- Channel-first: clinics adopt products that maximize throughput and reduce rework.
- Payer-first: formularies and coverage policies drive which MIGS devices become “preferred.”
- Evidence-first: durable outcome data and subgroup results determine long-term utilization.
Limitation that prevents quantitative financial mapping: no revenue-by-product or segment data is provided, and the constraints bar unsourced numeric claims.
Key Takeaways
- Glaukos’ competitive posture in glaucoma is most sensitive to device-procedure substitution (MIGS competition) and drug-device sustained delivery differentiation (release system and manufacturing IP).
- The strongest practical moat typically sits in device structure + implantation method claims, and in drug-loading/release manufacturing claims for delivery platforms.
- Generic-style entry risk depends on whether any Glaukos glaucoma products have Orange Book drug patent listings enabling ANDA/Paragraph IV dynamics; many glaucoma platforms are not governed by that framework.
- A rigorous exclusivity and litigation risk forecast requires product-specific FDA application identifiers and Orange Book/patent family mappings, without which a correct expiration timeline cannot be published.
FAQs
- Which FDA regulatory pathway governs Glaukos MIGS implants versus drug-device sustained delivery products?
- What claim elements most often determine infringement for glaucoma MIGS stent systems (structure, positioning method, or delivery tools)?
- How do settlement agreements in glaucoma device patent cases typically affect royalties and market entry timing?
- What reimbursement levers most influence adoption of combined cataract and MIGS procedures?
- When do competitors typically launch design-arounds in ophthalmic device patent landscapes, and what clinical evidence is required for adoption?
References (APA)
- FDA. Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. U.S. Food and Drug Administration.
- FDA. Device approvals and regulatory information (CDRH resources). U.S. Food and Drug Administration.
